中西医结合治疗桥本甲状腺炎疗效的Meta分析

Meta Analysis of Clinical Effects of Integrative Medicine in the Treatment of Hashimoto’s Thyroiditis

目的:系统评价中西医结合治疗桥本甲状腺炎(Hashimoto’s thyroiditis,HT)的疗效,为临床治疗桥本甲状腺炎提供循证医学证据。方法:搜索2009年1月至2019年12月发表的中西医结合与单纯西药治疗HT的随机对照试验(RCTs)。对这些文献进行筛选,提取符合纳入标准的数据。采用Stata 15.0软件分析数据,并对纳入研究进行发表偏倚分析和敏感性分析。结果:共纳入文献11篇,包括932例患者。观察组临床疗效明显优于单纯西药组(OR=1.24,95%CI[1.02,1.50],P<0.005)。观察组在改善甲状腺过氧化酶抗体(thyroid peroxidase antibody,TPOAb)和甲状腺球蛋白抗体(thyroglobulin antibody,TGAb)方面明显优于单纯西药组(SMD=-2.70,95%CI[-3.56,-1.83],P<0.01;SMD=-2.08,95%CI[-3.03,-1.34],P<0.05)。结论:中西医联合治疗桥本甲状腺炎临床疗效优于单纯西药组,可明显降低TGAb、TpoAb浓度。

Objective:To provide evidence-based medicine evidence for clinical therapy of Hashimoto’s thyroiditis(HT) by systematically assessing clinical effects of integrative medicine in the treatment of HT.Methods:After searching RCTs on integrative medicine and single Western medicine in treating HT between January,2009 and December,2019,the data were screened to extract the data met the inclusion criteria.Stata 15.0software was adopted to analyze the data,publication bias analysis and sensitivity analysis were performed for the included studies.Results:All 11 articles were included,involving 932 patients.Clinical effects of the observation group were notably better than these of single Western medicine group(OR=1.24,95%CI[1.02,1.50],P<0.005).The observation group was better than single Western medicine group in improving TPOAb and TGAb notably(SMD=-2.70,95%CI[-3.56,-1.83],P<0.01;SMD=-2.08,95%CI[-3.03,-1.34],P<0.05).Conclusion:Integrative medicine is superior to single Western medicine group in the treatment of HT,it could notably decrease the concentrations of TGAb and TpoAb.